ABIOMED Inc

ABIOMED — Q4 FY2022 Earnings Presentation

12 slides from ABIOMED's earnings presentation, Apr 28, 2022

  1. Slide 1: Q4 FY 2022 Earnings Call

    ® Recovering Hearts. Saving Lives. Q4 FY 2022 Earnings Call Financial Results & Operational Highlights 4/28/2022 Recovering Hearts. Saving Lives.

  2. Slide 2: Financial Results, Q4 FY 2022

    2 FINANCIAL RESULTS, Q4 FY 2022 Fiscal Year ends March 31 Revenue ($M) & Growth Rates Cash* ($M) $270 $979 $261 $932 $253 $248 $848 $862 $241 $805 YOY +17% +53% +18% +13% +12% Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 *Abiomed has no debt 1 Gross Margin % Operating Margin % 82.1% 8

  3. Slide 3: Financial Results, Annual

    3 FINANCIAL RESULTS, ANNUAL Fiscal Year ends March 31 Revenue ($M) & Growth Rate Cash* ($M) $1,032 $848 $979 $841 $769 $848 $594 $651 $513 $400 +33% +30% +9% +1% +22% FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 *Abiomed has no debt Gross Margin % Operating Margin

  4. Slide 4: U.S. Utilization Mix, Q4 FY 2022

    4 U.S. UTILIZATION MIX, Q4 FY 2022 Revenue by Impella® Device Utilization by Indication Impella 5.0® / 5.5 (20%) Other Impella RP® (4%) (3%) Emergent (58%) Impella 2.5® (2%) ® Impella CP ® Protected PCI (75%) (38%) Patient Performance Revenue Performance3 U.S. Hospital Site Penetration YoY Growth Yo

  5. Slide 5: The PROTECT Series of Studies

    5 THE PROTECT SERIES OF STUDIES Only FDA RCT and Studies Ever Conducted for Hemodynamically Supported High-Risk PCI PROTECT Studies 1252 1134 626 630 448 223 626 504 20 225 PROTECT I PROTECT II PROTECT III PROTECT IV FDA Pilot FDA Pivotal RCT FDA Prospective Study Pivotal RCT 2006-2007 2007-2010 201

  6. Slide 6: PROTECT III Shows Improved Outcomes in Contemporary Practices

    6 PROTECT III SHOWS IMPROVED OUTCOMES IN CONTEMPORARY PRACTICES 90-Day MACCE PROTECT III p<0.0001 p=0.03 31.0% P=0.037 21.9% 15.1% N = 210 N = 215 N = 390 IABP Impella 2.5 Impella 2.5 / CP PROTECT II1 PROTECT III2 N = number of patients with 90-day follow-up PII-like MACCE: Death, Stroke, MI, Repeat

  7. Slide 7: Continuous Safety Improvement Over Time in High-Risk PCI

    7 CONTINUOUS SAFETY IMPROVEMENT OVER TIME IN HIGH-RISK PCI PROTECT II RCT Major Bleeding5 14.6% 11.9% 8.2% 7.4% 6.1% 4.7% 4.0% PROTECT III 3.5% 2.7% 1.8% 1.3% N=79 N=82 N=61 N=59 N=64 N=68 N=99 N=25 N=57 N=4578 N=504 2008 2009 2010 2011 2012 2013-2017 2005-2014 2017-2020 PROTECT II RCT FDA PMA Data1

  8. Slide 8: Abiomed Clinical Trials and Innovation Milestones

    8 ABIOMED CLINICAL TRIALS AND INNOVATION MILESTONES Patient Study Detail Total Sites Status Enrollment New Indication for heart attacks without CGS. STEMI DTU Pivotal follows successful FDA Pilot study on 141 out of 788* 43 out of 60 TBD with COVID resolution FDA RCT Study reperfusion and ventricula

  9. Slide 9: FY 2023 Guidance

    9 FY 2023 GUIDANCE Abiomed FY’23 Guidance Revenue $1.14B - $1.18B +13% - 17% YOY Constant Currency* +11 - 15% YOY Reported GAAP Operating Margin % 23 - 24% *Constant currency: The company defines constant currency revenue growth as the change in revenue between current and prior year periods using a

  10. Slide 10: Appendix

    10 APPENDIX Recovering Hearts. Saving Lives.

  11. Slide 11: Evolution of Durable LVADs

    11 EVOLUTION OF DURABLE LVADS 1980s 1990s 2000s 2010s 2022 Large, heavy durable pulsatile pumps Large, invasive sternotomy The world’s first durable rotary blood pumps minimally invasive, intravascular Smaller, invasive durable durable LVAD rotary blood pumps First Patient on Support HVAD Heartmate

  12. Slide 12: Testing for Coronary Artery Disease

    12 TESTING FOR CORONARY ARTERY DISEASE Conclusion: The majority of patients hospitalized for new-onset HF did not receive testing for CAD either during the hospitalization or in the 90 days before and after. The rates of testing for CAD were higher in patients with LVEF ≤40% though remained low. The

ABIOMED — Q4 FY2022 Earnings Presentation on 6ix